IN2015KN00571A - - Google Patents
Info
- Publication number
- IN2015KN00571A IN2015KN00571A IN571KON2015A IN2015KN00571A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A IN 571KON2015 A IN571KON2015 A IN 571KON2015A IN 2015KN00571 A IN2015KN00571 A IN 2015KN00571A
- Authority
- IN
- India
- Prior art keywords
- vascular
- present disclosure
- ntprocnp
- finding
- subject
- Prior art date
Links
- 108010070573 NTproCNP Proteins 0.000 abstract 2
- 239000003550 marker Substances 0.000 abstract 2
- 230000035935 pregnancy Effects 0.000 abstract 2
- 230000002792 vascular Effects 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008774 maternal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261682729P | 2012-08-13 | 2012-08-13 | |
| PCT/NZ2013/000142 WO2014027899A1 (en) | 2012-08-13 | 2013-08-13 | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00571A true IN2015KN00571A (enrdf_load_stackoverflow) | 2015-07-17 |
Family
ID=50101335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN571KON2015 IN2015KN00571A (enrdf_load_stackoverflow) | 2012-08-13 | 2013-08-13 |
Country Status (9)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| EP2883060B1 (en) * | 2012-08-13 | 2018-03-21 | Otago Innovation Limited | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
| WO2014144231A1 (en) | 2013-03-15 | 2014-09-18 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| US20160106821A1 (en) * | 2014-10-20 | 2016-04-21 | Massachusetts Institute Of Technology | Functional ghrelin receptor antagonism during pregnancy to prevent stress-associated mental illness in offspring and mothers |
| WO2016138099A1 (en) | 2015-02-24 | 2016-09-01 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| TWI776812B (zh) * | 2016-06-02 | 2022-09-11 | 荷蘭商菲林公司 | 血管收縮素-1-受體拮抗劑 |
| WO2018216580A1 (ja) * | 2017-05-22 | 2018-11-29 | 東ソー株式会社 | アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬 |
| US12130294B2 (en) | 2018-04-10 | 2024-10-29 | Quanterix Corporation | Quantification of biomarkers present in physiological samples |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT407580B (de) * | 1999-08-20 | 2001-04-25 | Biomedica Gmbh | Indikatorpeptid zur diagnose und/oder vorhersage von cardiovasculären und/oder endothelialen erkrankungen, antikörperzusammensetzung und immunoassay |
| WO2004099139A1 (en) | 2000-09-15 | 2004-11-18 | Baylor University | Indole-containing compounds with anti-tubulin and vascular targeting activity |
| DE602004030342D1 (de) * | 2003-06-17 | 2011-01-13 | Otago Innovation Ltd | Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden |
| DE10338733A1 (de) | 2003-08-22 | 2005-03-24 | Berdel, Wolfgang E., Prof. Dr.med. | Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie |
| WO2008042855A2 (en) | 2006-09-29 | 2008-04-10 | The Trustees Of The University Of Pennsylvania | Use of ultrasound as an antivascular agent |
| CN103109192A (zh) * | 2010-06-18 | 2013-05-15 | 塞尚公司 | 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物 |
| EP2794646A4 (en) | 2011-12-23 | 2015-12-09 | Mayo Foundation | ASSESSMENT OF STRUCTURAL CHANGES AND RESULTS OF THE KIDNEYS |
| EP2883060B1 (en) * | 2012-08-13 | 2018-03-21 | Otago Innovation Limited | NT-proCNP AS A BIOMARKER OF VASCULAR DISORDERS AND PREGNANCY COMPLICATION |
-
2013
- 2013-08-13 EP EP13829360.0A patent/EP2883060B1/en not_active Not-in-force
- 2013-08-13 AU AU2013303302A patent/AU2013303302B2/en not_active Ceased
- 2013-08-13 JP JP2015527420A patent/JP6423788B2/ja not_active Expired - Fee Related
- 2013-08-13 WO PCT/NZ2013/000142 patent/WO2014027899A1/en active Application Filing
- 2013-08-13 CN CN201380053106.1A patent/CN104937420B/zh not_active Expired - Fee Related
- 2013-08-13 SG SG11201501145SA patent/SG11201501145SA/en unknown
- 2013-08-13 US US14/421,423 patent/US10012656B2/en not_active Expired - Fee Related
- 2013-08-13 SG SG10201700872TA patent/SG10201700872TA/en unknown
- 2013-08-13 IN IN571KON2015 patent/IN2015KN00571A/en unknown
- 2013-08-13 CA CA2882116A patent/CA2882116A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013303302B2 (en) | 2017-10-12 |
| AU2013303302A1 (en) | 2015-03-12 |
| CN104937420B (zh) | 2018-07-03 |
| JP6423788B2 (ja) | 2018-11-14 |
| US10012656B2 (en) | 2018-07-03 |
| US20150241451A1 (en) | 2015-08-27 |
| CN104937420A (zh) | 2015-09-23 |
| EP2883060A1 (en) | 2015-06-17 |
| SG10201700872TA (en) | 2017-04-27 |
| CA2882116A1 (en) | 2014-02-20 |
| WO2014027899A1 (en) | 2014-02-20 |
| EP2883060B1 (en) | 2018-03-21 |
| JP2015526725A (ja) | 2015-09-10 |
| EP2883060A4 (en) | 2016-06-29 |
| SG11201501145SA (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015KN00571A (enrdf_load_stackoverflow) | ||
| PH12018500513A1 (en) | Methods for diagnosing and evaluating non-alcoholic steatohepatitis | |
| BR112017011172A2 (pt) | atenuação de interferência para sinais de referência de posicionamento | |
| MX2016013635A (es) | Métodos para aumentar los niveles de eritrocitos y tratar de la enfermedad de células falciformes. | |
| MX2015015784A (es) | Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino. | |
| HK1218576A1 (zh) | 结核病生物标志物及其用途 | |
| EA201591582A1 (ru) | Анализ транскриптома материнской плазмы с применением массивного параллельного секвенирования рнк | |
| MX2018001759A (es) | Tratamiento acido para fertilizantes para incrementar al solubilidad y disponibilidad del zinc. | |
| BR112015030293A2 (pt) | compensação de dados magnéticos para inspeções de mapeamento de veículo submarino autônomo | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| BR112015017767A2 (pt) | sistema para detectar estágios do sono de um indivíduo, método para detectar estágios do sono de um indivíduo, e, sistema configurado para detectar estágios do sono de um indivíduo | |
| WO2017031067A3 (en) | Biomarkers for treatment of alopecia areata | |
| WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
| WO2014169226A3 (en) | Methods of diagnosing and treating chronic pain | |
| EP3988673A3 (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| BR112018071467A2 (pt) | método de tratamento ou prevenção de patologias hepáticas | |
| PH12018501443A1 (en) | Methods of administering hepcidin | |
| PH12015502687A1 (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| WO2017027391A3 (en) | Genetic abnormalities in plasma cell dyscrasias | |
| FR2979346B1 (fr) | Nanocorps anti-vcam-1 | |
| WO2015069883A3 (en) | Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same | |
| MX2019002818A (es) | Metodos para detectar anticuerpos neutralizantes anti-leptina. | |
| WO2015085055A3 (en) | Methods of treating or preventing pruritis by blocking natriuretic polypeptide b | |
| WO2014100602A8 (en) | Treatment of egf-receptor dependent pathologies | |
| MX2014013049A (es) | Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante. |